Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference

New York — February 8, 2018 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome and other central nervous system (CNS) diseases, announced today that its President & Chief Executive Officer, Christopher U. Missling,…